TENS Neurostimulator

TENS Neurostimulator
Details:
Galvanic isolation between the two channels is maintained through optocouplers providing 4,000V DC breakdown isolation, paired with custom-wound planar pulse transformers with physical winding separations exceeding 6.0 mm.

Inter-channel stray capacitance is restricted below 8 pF, suppressing displacement crosstalk currents below 3 uA.

The H-bridge output drives a symmetrical biphasic pulse: the primary stimulating phase is matched with an active, polarity-reversed phase of equal volt-second area, followed by an active discharge cycle through series-stacked 250V metallized film capacitors to keep net direct-current leakage strictly below 0.005 uC per cycle.

The mechanical housing is molded from high-impact medical-grade ABS/PC alloy (UL 94V-0 flame retardance) featuring an overmolded thermoplastic elastomer (TPE) perimeter bumper that withstands 1.5-meter drop impacts onto concrete.

Each production unit undergoes 100% automated test equipment (ATE) verification across an RC load network (100, 500, 1,000, 1,500, and 3,000 Ohm parallel with 0.1 uF).

Testing verifies phase charge balance, rise times, slew rates, and the 10-millisecond open-circuit cutoff response. The minimum contract manufacturing run is 5,000 units.
Send Inquiry
Download
Description
Technical Parameters
 

OEM TENS Neurostimulator | Dual-Channel Neuromodulation | TOP-RANK

 

 

B2B contract manufacturing of prescription-grade TENS neurostimulators. Features dual isolated constant-current channels, 2/100 Hz dense-disperse modulation, 0.1 uC phase-charge titration, active edge-slew limiting, 120V dynamic compliance rails, and IEC 60601-2-10 compliance.

 

Product Overview

 

The clinical TENS neurostimulator functions as a targeted neuro-pathway generator designed for hospital pain clinics, neurological physical therapy suites, and outpatient rehabilitation departments. While basic consumer TENS units focus on non-specific surface parasthesia, this neurostimulation platform interfaces with central descending pain inhibition pathways-specifically activating the Diffuse Noxious Inhibitory Controls (DNIC) and inducing differential neuropeptide cascade release via alternating dense-disperse pulse trains.

Clinical deployment of generic stimulators reveals three hardware-level failure modes during daily patient handling:

  • Current Density Flashover from Electrode Edge Peeling: When an adhesive hydrogel pad partially detaches or loses edge moisture due to body contour flexion, the conductive surface area shrinks from 25 cm² down to less than 2 cm². Unregulated stimulators continue dumping full current through the remaining contact patch. Local current density spikes past 2.0 mA/cm², generating concentrated micro-arcs that burn epidermal tissue and trigger acute pain shocks.
  • Opioid Receptor Exhaustion from Monotonous Firing: Applying a fixed-frequency stimulus (such as continuous 80 Hz or 100 Hz) recruits only a single opioid receptor class (primarily delta-opioid receptors via enkephalin release). Within 20 to 30 minutes, pre-synaptic receptor down-regulation causes clinical tolerance. The analgesic threshold decays, and the patient experiences breakthrough pain.
  • Switching Transients Inducing False Triggers in Adjacent Diagnostics: Low-cost output bridges switch inductive loads rapidly without slew-rate control. The resulting high-frequency ringing (f > 30 MHz) radiates through patient leadwires, corrupting signals on nearby surface electromyography (sEMG) or diagnostic ECG monitors in the same treatment bay.

This console integrates two galvanically isolated output stages driven by a closed-loop 120V compliance rail. The core processor executes an active phase-charge titration engine that measures delivered micro-coulombs per phase (Q = ∫ i dt) at a resolution of 0.1 uC. An alternating 2/100 Hz dense-disperse algorithm drives dual-pathway endorphin and dynorphin release to bypass receptor tolerance. Output stages incorporate edge-slew limiting circuitry to clamp dI/dt, preventing micro-arcing during pad dry-out. We contract-manufacture this platform for medical rehabilitation brands, clinical equipment distributors, and private-label physical therapy device OEMs.

 

Technical & Engineering Description

 

Continuous production of the TENS neurostimulator executes in ISO 13485-certified Class 8 cleanrooms. The circuit layout is implemented on an industrial 4-layer FR-4 printed circuit board with partitioned copper planes isolating digital processing, high-voltage boost stages, and the two floating analog driver sections.

The processing core features a 32-bit ARM Cortex-M4 microcontroller operating at 120 MHz. The power conversion stage employs an active, inductive DC-DC boost converter operating at 250 kHz, boosting 3.7V battery power up to a dynamically regulated 120V compliance voltage. Output current delivery is regulated through discrete bipolar current-mirror stages driven by an array of matched N-channel and P-channel MOSFETs configured in a full H-bridge. A precision operational-amplifier integration circuit samples delivered current across 0.05% tolerance shunt resistors at 1.0 MHz, integrating current over time to calculate real-time phase charge (Q). If the phase charge exceeds preset clinical limits or if the differential current indicates sudden impedance shifts (dR/dt > 1,000Ωms), firmware immediately clamps the drive gates.

Galvanic isolation between the two channels is maintained through optocouplers providing 4,000V DC breakdown isolation, paired with custom-wound planar pulse transformers with physical winding separations exceeding 6.0 mm. Inter-channel stray capacitance is restricted below 8 pF, suppressing displacement crosstalk currents below 3 uA. The H-bridge output drives a symmetrical biphasic pulse: the primary stimulating phase is matched with an active, polarity-reversed phase of equal volt-second area, followed by an active discharge cycle through series-stacked 250V metallized film capacitors to keep net direct-current leakage strictly below 0.005 uC per cycle.

The mechanical housing is molded from high-impact medical-grade ABS/PC alloy (UL 94V-0 flame retardance) featuring an overmolded thermoplastic elastomer (TPE) perimeter bumper that withstands 1.5-meter drop impacts onto concrete. Each production unit undergoes 100% automated test equipment (ATE) verification across an RC load network (100, 500, 1,000, 1,500, and 3,000 Ohm parallel with 0.1 uF). Testing verifies phase charge balance, rise times, slew rates, and the 10-millisecond open-circuit cutoff response. The minimum contract manufacturing run is 5,000 units.

 

Key Features

 

  • Alternating 2/100 Hz Dense-Disperse Neuromodulation (Dual Opioid Peptide Cascade Without Receptor Habituation) 

    Continuous single-frequency stimulation (such as fixed 100 Hz) causes rapid analgesic decay: the constant pulse train exclusively stimulates delta-opioid receptors via enkephalin release, leading to receptor internalisation and loss of pain inhibition within 30 minutes. Our neurostimulator incorporates an algorithmic 2/100 Hz dense-disperse modulation engine (Han's protocol). The microcontroller automatically alternates between a low-frequency 2 Hz pulse train (dense mode, 3-second cycle) and a high-frequency 100 Hz pulse train (disperse mode, 3-second cycle). The 2 Hz phase recruits low-threshold ergoreceptors to trigger hypothalamic release of beta-endorphins and endomorphins acting on mu-opioid receptors. The 100 Hz phase depolarizes large-diameter A-beta sensory afferents, driving spinal cord release of dynorphin acting on kappa-opioid receptors. By sequentially shifting the molecular target between mu-, delta-, and kappa-receptor subtypes, the device sustains profound central and spinal analgesia across multi-hour clinical sessions without inducing narcotic-like habituation.

     

  • Real-Time Micro-Coulomb Phase-Charge Titration (Preventing Localized Dermal Burns from Electrode Desiccation) 

    When a hydrogel electrode begins to lift off or dry out, the conductive contact area decreases while overall circuit resistance increases. Generic constant-current stimulators respond by raising compliance voltage to force the selected milliampere setting through the shrinking area, creating a localized current density spike (J = I / A) that burns epidermal tissue. We integrate an active Coulombic titration engine sampling at 1.0 MHz across current-sensing shunts. The processor integrates the area under the current-time curve (Q = ∫ i dt) for each individual phase. If local tissue impedance jumps ($dR/dt > 1,000\ \Omega/\text{ms}$) or if the instantaneous phase charge exceeds a safety ceiling of 35 uC, the hardware clamps drive pulses within 10 microseconds. Output current rolls back automatically to match the reduced effective contact area, eliminating the high current densities that cause skin burns and sharp electrical shocks during pad movement.

     

  • Controlled Edge-Slew Limiting Architecture (Suppressing High-Frequency RF Noise Radiating into Diagnostic Equipment) 

    Standard power MOSFET bridge drivers execute abrupt transitions with rise times under 50 nanoseconds. When driving reactive leadwires and biological skin-electrode loads, these fast step functions (dV/dt > 200 V/μs) excite parasitic inductances, creating high-frequency ringing that radiates EMI noise into nearby diagnostic instrumentation. Our output stage features an active RC-filtered push-pull gate drive network that clamps the current slew rate strictly below 50mA/μs. The edges of the biphasic square pulses are shaped with controlled microsecond transitions without rounding the active plateau. This soft-switching approach suppresses radio-frequency emissions above 30 MHz by over 28 dB, complying with IEC 60601-1-2 Class B hospital limits while maintaining the square-wave plateau required for selective nerve excitation.

 

Applications

 

Hospital Multidisciplinary Pain Clinics & Palliative Care

Prescribed for intractable neuropathic conditions, including post-herpetic neuralgia (PHN), complex regional pain syndrome (CRPS), and chronic phantom limb pain, utilizing the 2/100 Hz dense-disperse protocol to sustain opioid-independent analgesia.

 

Post-Surgical Orthopedic Mobilization

Bedside neurostimulation deployed following joint replacement (TKA/THA) and spine stabilization surgery, providing continuous presynaptic pain gating during active-assisted physical therapy sessions without causing motor-threshold spasms.

 

Diabetic Sensory Neuropathy Rehabilitation Centers

Low-frequency sensory re-education protocols applied to distal extremities to relieve burning dysesthesias, improve localized skin perfusion, and retard sensory nerve degeneration in Type II diabetic patients.

OEM & Private Label

 

  • Custom Chassis Tooling, UI Design & Accessory Integration : We provide turnkey contract manufacturing for custom handheld enclosures, clinician-grade desktop cradles, and backlit displays. The control interface can be configured with an optical rotary encoder, sealed silicone touch keys, or a 3.5-inch color display. Firmware options include protected clinician lockout modes, customizable therapy timers (1 to 60 minutes), and USB/Bluetooth therapy logging. All patient connection ports feature recessed 2.0 mm touch-proof DIN sockets bundled with shielded, Kevlar-reinforced twin-lead wire harnesses.

  • Two-Center Supply Chain Mechanics : High-density SMT circuit assembly, GaN/MOSFET driver calibration, custom pulse transformer planar winding, and primary functional testing execute natively inside our primary China facility. Plastic enclosure injection molding, display module integration, battery safety circuit testing, 48-hour burn-in stress testing, final cleanroom packaging, and ocean container palletization route through our Vietnam hub, shielding international B2B buyers from regional medical device tariffs and Section 301 duties.

 

Certifications

 

  • ANSI/AAMI NS4 & IEC 60601-2-10 Compliance : Production master units undergo comprehensive testing in accredited independent laboratories confirming compliance with ANSI/AAMI NS4 (Transcutaneous electrical nerve stimulators), IEC 60601-1 (Class II, Type BF applied parts), IEC 60601-1-2 (EMC Class B hospital standards), and IEC 60601-2-10. Output current ceilings (<120 mA peak), maximum phase energy limits (<300 mJ into 1,000 Ohm), and the 10-millisecond open-circuit cutoff response are interlocked in hardware. 

  • MDSAP & ISO 13485 Certified Manufacturing Oversight : Surface-mount lines, cable assembly decks, and testing stations operate strictly under certified ISO 13485:2016 and MDSAP regulatory frameworks (covering US FDA 21 CFR 820, Health Canada, TGA Australia). Unbroken electronic Device History Records (DHR) track every discrete semiconductor, planar transformer, and power supply lot from component reels to outbound master shipping cartons.

 

Technical FAQ

Q: Why does 2/100 Hz dense-disperse stimulation produce longer post-treatment analgesic carry-over than fixed 100 Hz TENS, and how does the firmware handle the frequency transition without current spikes?

A: Fixed 100 Hz stimulation operates primarily via spinal gate control (A-beta fiber recruitment activating inhibitory interneurons in the substantia gelatinosa) alongside enkephalin-mediated delta-opioid receptor activation. This effect dissipates rapidly within 15 to 30 minutes after power-down as neurotransmitter reserves deplete. In contrast, 2/100 Hz dense-disperse stimulation recruits both low-threshold mechanoreceptors (at 2 Hz) and high-threshold sensory afferents (at 100 Hz), driving the simultaneous release of beta-endorphin, endomorphin, and dynorphin in the central nervous system. These peptide combinations demonstrate synergistic binding affinity across mu- and kappa-opioid receptors, generating an analgesic carry-over that persists for 2 to 5 hours after the session ends. The engineering challenge in dense-disperse stimulation occurs at the transition boundary (switching from 2 Hz to 100 Hz and vice versa): switching inductive boost converter duty cycles abruptly causes output current surges. Our firmware addresses this by executing a zero-crossing boundary transition. When the 3-second timer expires, the microprocessor detects the zero-current state between biphasic pulses and resets the boost stage PWM duty cycle within a 40-microsecond window. The phase duration automatically steps down as frequency accelerates, holding total charge delivery per second constant across the frequency shift without transient current spikes.

Q: How does the phase-charge titration circuit identify electrode lift-off before current density reaches painful or damaging levels?

A: Conventional stimulators detect open circuits by measuring absolute voltage or average DC resistance over several pulse cycles, a slow detection loop taking 100 to 500 milliseconds. If an electrode peels off partially during a high-current treatment (e.g., 60 mA into an area that shrinks from 20 cm² down to 1 cm²), the current density spikes to 60 mA/cm² for hundreds of milliseconds before the system reacts, causing skin burns. Our console detects contact degradation on a pulse-by-pulse basis using an analog integrator coupled to a 12-bit ADC sampling at 1.0 MHz. The system monitors the rate of impedance change (dR/dt) within the first 5 microseconds of each individual pulse. When an electrode border detaches, the interface capacitance drops and series resistance jumps sharply, causing a high dR/dt slope. If the circuit detects that the instantaneous driving voltage required to push the set current exceeds a dynamic safety threshold calculated from the previous cycle, the hardware trips a low-side MOSFET to ground within 10 microseconds, truncating the pulse. The unit halts output, alarms with an acoustic signal, and displays an electrode fault message before dangerous energy can concentrate across the skin boundary.

 

 

Physical therapy equipment distributors, clinical biomedical procurement managers, and specialized rehabilitation brand operators can request complete ANSI/AAMI NS4 electrical compliance dossiers, 2/100 Hz dense-disperse waveform oscillograms, and functional evaluation consoles with clinical leadwire and electrode suites. 

👉 [Request TENS Neurostimulator Evaluation Console]

 

Hot Tags: tens neurostimulator, China tens neurostimulator manufacturers, suppliers, factory, TENS Electro Stimulator, Medical TENS Unit, best TENS machine for osteoarthritis, TENS Unit Machine, TENS Therapy Machine, Transcutaneous Nerve Stimulation

Specifications

 

Device name

TENS-806

Power sources

3.7 V Li-ion battery

Power supply

Input: 100-240V AC, 50/60Hz,0.2A; Output: 5V DC, 300mA

Output channel

Dual channel

Waveform

Bi-phase square-wave pulse

Output current

Max. 120mA (at 500ohm load)

Output intensity

0 to 40 levels, adjustable

Treatment mode:

TENS,EMS

Number of programs

26 program

Pulse rate

2Hz ~ 120Hz

Pulse width

50uS ~ 300uS

Treatment time

5 minutes ~ 90 minutes

Operating condition

5° C to 40° C with a relative humidity of 15%-93%,
atmospheric pressure from 700 hPa to 1060 hPa

Storage condition

-10° C to 55° C with a relative humidity of 10%-
95%, atmospheric pressure from 700 hPa to
1060 hPa

Dimension

109*55*18mm (L x W x T)

Weight

About 73g

Automatic shutof

1 minute

Classification

BF type applied part, internal power equipment, IP22

Size of electrodes pad

40x40mm, square

Output precision

±20% error is allowed for all the output parameters

Send Inquiry